Morgan Stanley’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74.6M | Sell |
139,009
-52,285
| -27% | -$26.8M | ﹤0.01% | 1827 |
|
|
2026
Q1 | $100M | Buy |
191,294
+40,832
| +27% | +$19.5M | 0.01% | 1440 |
|
|
2025
Q4 | $87.6M | Sell |
150,462
-99,185
| -40% | -$50.7M | 0.01% | 1567 |
|
|
2025
Q3 | $115M | Buy |
249,647
+1,685
| +0.7% | +$629K | 0.01% | 1298 |
|
|
2025
Q2 | $75M | Sell |
247,962
-136,866
| -36% | -$40.8M | ﹤0.01% | 1557 |
|
|
2025
Q1 | $127M | Buy |
384,828
+166,347
| +76% | +$54.7M | 0.01% | 1084 |
|
|
2024
Q4 | $67.4M | Sell |
218,481
-50,913
| -19% | -$14.3M | ﹤0.01% | 1571 |
|
|
2024
Q3 | $57.2M | Buy |
269,394
+49,363
| +22% | +$12.6M | ﹤0.01% | 1704 |
|
|
2024
Q2 | $61.6M | Sell |
220,031
-68,575
| -24% | -$16.3M | ﹤0.01% | 1558 |
|
|
2024
Q1 | $77.1M | Buy |
288,606
+136,688
| +90% | +$32.2M | 0.01% | 1371 |
|
|
2023
Q4 | $35.2M | Sell |
151,918
-19,855
| -12% | -$3.47M | ﹤0.01% | 2083 |
|
|
2023
Q3 | $25.1M | Buy |
171,773
+97,480
| +131% | +$18.3M | ﹤0.01% | 2217 |
|
|
2023
Q2 | $17.2M | Sell |
74,293
-73,486
| -50% | -$19.9M | ﹤0.01% | 2632 |
|
|
2023
Q1 | $35.8M | Buy |
147,779
+38,359
| +35% | +$10.5M | ﹤0.01% | 1861 |
|
|
2022
Q4 | $31.8M | Buy |
109,420
+50,356
| +85% | +$4.92M | ﹤0.01% | 1906 |
|
|
2022
Q3 | $3.84M | Sell |
59,064
-23,889
| -29% | -$1.66M | ﹤0.01% | 3907 |
|
|
2022
Q2 | $5.94M | Sell |
82,953
-15,071
| -15% | -$1.11M | ﹤0.01% | 3603 |
|
|
2022
Q1 | $9.62M | Buy |
98,024
+49,686
| +103% | +$4.19M | ﹤0.01% | 2946 |
|
|
2021
Q4 | $4.1M | Sell |
48,338
-19,830
| -29% | -$1.63M | ﹤0.01% | 3921 |
|
|
2021
Q3 | $5.44M | Sell |
68,168
-25,509
| -27% | -$2.2M | ﹤0.01% | 3597 |
|
|
2021
Q2 | $9.13M | Sell |
93,677
-169,221
| -64% | -$20M | ﹤0.01% | 3097 |
|
|
2021
Q1 | $30.8M | Buy |
262,898
+211,311
| +410% | +$24.6M | ﹤0.01% | 1545 |
|
|
2020
Q4 | $5.73M | Buy |
51,587
+23,527
| +84% | +$2.88M | ﹤0.01% | 3104 |
|
|
2020
Q3 | $3.33M | Buy |
28,060
+1,406
| +5% | +$153K | ﹤0.01% | 3133 |
|
|
2020
Q2 | $3.02M | Buy |
26,654
+1,880
| +8% | +$185K | ﹤0.01% | 3188 |
|
|
2020
Q1 | $1.65M | Buy |
24,774
+1,110
| +5% | +$92.5K | ﹤0.01% | 3526 |
|
|
2019
Q4 | $2.16M | Sell |
23,664
-11,319
| -32% | -$1.1M | ﹤0.01% | 3977 |
|
|
2019
Q3 | $3.02M | Buy |
34,983
+20,479
| +141% | +$1.92M | ﹤0.01% | 3412 |
|
|
2019
Q2 | $1.52M | Buy |
14,504
+1,064
| +8% | +$114K | ﹤0.01% | 3986 |
|
|
2019
Q1 | $1.68M | Sell |
13,440
-50,539
| -79% | -$6.28M | ﹤0.01% | 3728 |
|
|
2018
Q4 | $7.21M | Buy |
63,979
+42,296
| +195% | +$6.55M | ﹤0.01% | 2477 |
|
|
2018
Q3 | $4.64M | Sell |
21,683
-2,089
| -9% | -$524K | ﹤0.01% | 3263 |
|
|
2018
Q2 | $6.65M | Buy |
23,772
+11,472
| +93% | +$2.01M | ﹤0.01% | 2828 |
|
|
2018
Q1 | $1.44M | Buy |
12,300
+2,183
| +22% | +$269K | ﹤0.01% | 4282 |
|
|
2017
Q4 | $928K | Buy |
10,117
+4,471
| +79% | +$255K | ﹤0.01% | 4593 |
|
|
2017
Q3 | $255K | Buy |
5,646
+1,718
| +44% | +$32.2K | ﹤0.01% | 5230 |
|
|
2017
Q2 | $63K | Buy |
3,928
+1,756
| +81% | +$27.4K | ﹤0.01% | 5793 |
|
|
2017
Q1 | $33K | Buy |
2,172
+1,840
| +554% | +$28.9K | ﹤0.01% | 5949 |
|
|
2016
Q4 | $5K | Buy |
332
+82
| +33% | +$1.32K | ﹤0.01% | 6275 |
|
|
2016
Q3 | $3K | Sell |
250
-2
| -0.8% | -$19 | ﹤0.01% | 6323 |
|
|
2016
Q2 | $3K | Sell |
252
-79
| -24% | -$948 | ﹤0.01% | 6303 |
|
|
2016
Q1 | $3K | Sell |
331
-763
| -70% | -$6.37K | ﹤0.01% | 6359 |
|
|
2015
Q4 | $14K | Sell |
1,094
-134
| -11% | -$3.68K | ﹤0.01% | 6144 |
|
|
2015
Q3 | $74K | Sell |
1,228
-324
| -21% | -$23.4K | ﹤0.01% | 5559 |
|
|
2015
Q2 | $121K | Sell |
1,552
-3,929
| -72% | -$330K | ﹤0.01% | 5486 |
|
|
2015
Q1 | $371K | Sell |
5,481
-12,532
| -70% | -$1.07M | ﹤0.01% | 4842 |
|
|
2014
Q4 | $1.67M | Buy |
18,013
+9,282
| +106% | +$960K | ﹤0.01% | 3717 |
|
|
2014
Q3 | $919K | Buy |
8,731
+5,522
| +172% | +$768K | ﹤0.01% | 4107 |
|
|
2014
Q2 | $460K | Buy |
3,209
+821
| +34% | +$120K | ﹤0.01% | 4642 |
|
|
2014
Q1 | $361K | Buy |
2,388
+551
| +30% | +$109K | ﹤0.01% | 4772 |
|
|
2013
Q4 | $337K | Buy |
1,837
+609
| +50% | +$112K | ﹤0.01% | 4741 |
|
|
2013
Q3 | $272K | Sell |
1,228
-3,121
| -72% | -$664K | ﹤0.01% | 4720 |
|
|
2013
Q2 | $760K | Buy |
+4,349
| New | +$1.13M | ﹤0.01% | 3941 |
|
Other funds holding MDGL
BBA
RI
JT
ACA
PC
Morgan Stanley's MDGL Position: Q2 2026 in Review
Morgan Stanley reduced its Madrigal Pharmaceuticals (MDGL) stake by 27% in Q2 2026, selling an estimated $26.8M and leaving 139,009 shares worth $74.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.
Morgan Stanley first reported a position in MDGL in Q2 2013 and has held it in 53 quarters since. The position peaked at $127M in Q1 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- Morgan Stanley held 139,009 shares of Madrigal Pharmaceuticals worth $74.6M as of Q2 2026.
- Morgan Stanley sold 52,285 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $26.8M.
- Madrigal Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1827 holding.
- Morgan Stanley first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's Madrigal Pharmaceuticals position peaked at $127M in Q1 2025.
- 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.